Halozyme completes $1.5 billion convertible notes sale due 2033
Halozyme Therapeutics completed the sale of $1,500.0 million of 1.50% Convertible Senior Notes due 2033 on September 22, 2026, including $200.0 million from the initial purchasers' option. The company received net proceeds of approximately $1,471.1 million and plans to use part of them to repurchase existing 2027 and 2028 convertible notes, which adds new debt while potentially reducing older debt.
Key points
- $1,500.0 million aggregate principal of 1.50% Convertible Senior Notes due 2033 sold, including a $200.0 million option exercise
- Net proceeds of approximately $1,471.1 million, with $187.5 million used to fund capped call transactions
- Expected repurchases of about $217.0 million of 2027 Notes and about $435.5 million of 2028 Notes, including accrued interest
- Initial conversion price of approximately $139.84 per share; interest paid semi-annually starting April 1, 2027
The filing
Written by AI on Nov 8, 2026, 1:12 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 22, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.